You searched for side effects - Page 89 of 311 - Medivizor
Navigation Menu

The impact of a pharmaceutical care program for patients with B-cell lymphoma treated with ibrutinib

The impact of a pharmaceutical care program for patients with B-cell lymphoma treated with ibrutinib

Posted by on Jul 5, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with B-cell non-Hodgkin's lymphoma (NHL). This study concluded that the management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better tolerance than...

Read More

The impact of a pharmaceutical care program for patients with chronic lymphocytic leukemia treated with ibrutinib

The impact of a pharmaceutical care program for patients with chronic lymphocytic leukemia treated with ibrutinib

Posted by on Jul 5, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of a pharmaceutical care program on the safety and effectiveness of ibrutinib in patients with chronic lymphocytic leukemia. This study concluded that management of ibrutinib treatment by using a pharmaceutical care program results in improved survival and better...

Read More

Prolonged-release melatonin improves the quality of sleep of patients with Parkinson’s disease

Prolonged-release melatonin improves the quality of sleep of patients with Parkinson’s disease

Posted by on Jul 5, 2020 in Parkinson's Disease | 0 comments

In a nutshell This study investigated the effectiveness and safety of prolonged-release melatonin (PRM; Circadin) in patients with Parkinson's disease (PD) and poor sleep quality. Researchers suggested that PRM is a good and safe option do treat these patients. Some background Parkinson's disease (PD) is a chronic disorder that affects 60,000...

Read More

Combined S-1 chemotherapy improves the outcomes of patients with advanced colorectal cancer

Combined S-1 chemotherapy improves the outcomes of patients with advanced colorectal cancer

Posted by on Jul 1, 2020 in Colorectal cancer | 0 comments

In a nutshell This study compared two different chemotherapy treatments in metastatic colorectal cancer (mCRC; spread to other parts of the body). Researchers suggested that 24-hour infused irinotecan (Camptosar) plus oral S-1 (Teysuno) chemotherapy and bevacizumab (Avastin) is well tolerated and associated with improved outcomes. Some background...

Read More

Is tapering DMARD treatment safe and effective in rheumatoid arthritis?

Is tapering DMARD treatment safe and effective in rheumatoid arthritis?

Posted by on Jun 28, 2020 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated treatment tapering strategies (TTS) in patients with rheumatoid arthritis (RA). They found that drug-free remission (DFR) can be achieved in a small number of patients. Some background Rheumatoid arthritis (RA) is a chronic condition. It is caused by excessive inflammation. This leads to painful swelling in...

Read More

Vibegron improves the treatment outcomes of patients with overactive bladder

Vibegron improves the treatment outcomes of patients with overactive bladder

Posted by on Jun 28, 2020 in Overactive bladder | 0 comments

In a nutshell This study reviewed the effectiveness and safety of vibegron in the treatment of overactive bladder (OAB). Researchers suggested that vibegron was associated with improved OAB symptoms and was well tolerated. Some background OAB consists of a frequent and sudden urge to urinate that may be difficult to control. It is present in 18.6% of...

Read More

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Does pembrolizumab added to chemotherapy before surgery improve the outcomes of patients with early triple negative breast cancer?

Posted by on Jun 28, 2020 in Breast cancer | 0 comments

In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...

Read More

Does olaparib increase survival in patients with metastatic castration-resistant prostate cancer?

Does olaparib increase survival in patients with metastatic castration-resistant prostate cancer?

Posted by on Jun 27, 2020 in Prostate cancer | 0 comments

In a nutshell This study assessed whether olaparib (Lynparza) affected progression-free survival (PFS; survival without cancer worsening) in patients with metastatic castration-resistant prostate cancer (mCRPC) and certain genetic mutations (abnormalities). The study found that olaparib improved PFS in these patients. Some...

Read More